| Symbol | SIGA |
|---|---|
| Name | SIGA TECHNOLOGIES INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 31 EAST 62ND STREET, NEW YORK, NY 10065 |
| Telephone | 212-672-9100 |
| Fax | — |
| — | |
| Website | https://www.siga.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001010086 |
| Description | SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The companys lead product is TPOXX, an orally administered antiviral drug for the treatment of human smallpox disease caused by the variola virus. Its products target orthopoxvirus infections including smallpox. Additional info from NASDAQ: |
New Form S-8 - SIGA TECHNOLOGIES INC <b>Filed:</b> 2026-06-25 <b>AccNo:</b> 0001140361-26-026380 <b>Size:</b> 222 KB
Read moreMarshall Joseph W III 🟡 adjusted position in 26.9K shares (2 derivative) of SIGA TECHNOLOGIES INC (SIGA) at $4.39 Transaction Date: Jun 09, 2026 | Filing ID: 266423
Read moreKEANE JOHN M 🟡 adjusted position in 26.9K shares (2 derivative) of SIGA TECHNOLOGIES INC (SIGA) at $4.39 Transaction Date: Jun 09, 2026 | Filing ID: 266418
Read moreFord Harold Eugene Jr. 🟡 adjusted position in 26.9K shares (2 derivative) of SIGA TECHNOLOGIES INC (SIGA) at $4.39 Transaction Date: Jun 09, 2026 | Filing ID: 266414
Read morePhillips Holly L. 🟡 adjusted position in 26.9K shares (2 derivative) of SIGA TECHNOLOGIES INC (SIGA) at $4.39 Transaction Date: Jun 09, 2026 | Filing ID: 266410
Read moreNemirovsky Julian 🟡 adjusted position in 26.9K shares (2 derivative) of SIGA TECHNOLOGIES INC (SIGA) at $4.39 Transaction Date: Jun 09, 2026 | Filing ID: 266406
Read moreDURNAN JAYMIE A 🟡 adjusted position in 26.9K shares (2 derivative) of SIGA TECHNOLOGIES INC (SIGA) at $4.39 Transaction Date: Jun 09, 2026 | Filing ID: 266399
Read moreNabel Gary J. 🟡 adjusted position in 26.9K shares (2 derivative) of SIGA TECHNOLOGIES INC (SIGA) at $4.39 Transaction Date: Jun 09, 2026 | Filing ID: 266390
Read moreNew Form DEFA14A - SIGA TECHNOLOGIES INC <b>Filed:</b> 2026-05-08 <b>AccNo:</b> 0001140361-26-020020 <b>Size:</b> 174 KB
Read more(10% Negative) SIGA TECHNOLOGIES INC (SIGA) Reports Q2 2026 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05380752 | Tecovirimat Intravenous Treatment for Orthopox Virus Exposure | — | Orthopox Virus Infection | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT05534984 | Study of Tecovirimat for Human Mpox Virus | Phase3 | MPOX | Terminated | 2022-09-08 | 2025-02-22 | ClinicalTrials.gov |
| NCT04485039 | Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders | Phase4 | Smallpox | Completed | 2022-06-08 | 2023-04-23 | ClinicalTrials.gov |
| NCT04957485 | Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orall… | Phase2 | Smallpox | Active_Not_Recruiting | 2022-04-05 | 2027-01-01 | ClinicalTrials.gov |
| NCT04971109 | Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for… | Phase3 | Smallpox | Completed | 2022-03-29 | 2023-05-12 | ClinicalTrials.gov |
| NCT03972111 | A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox | — | Smallpox | Withdrawn | 2020-01-01 | 2024-09-30 | ClinicalTrials.gov |
| NCT04392739 | Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG | Phase4 | Smallpox | Completed | 2019-07-19 | 2019-12-05 | ClinicalTrials.gov |
| NCT02474589 | A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Or… | Phase3 | Smallpox | Completed | 2015-06-19 | 2016-08-24 | ClinicalTrials.gov |
| NCT00907803 | Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246 | Phase2 | Orthopoxviral Disease | Completed | 2009-06-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00728689 | Phase I Trial of an Investigational Small Pox Medication | Phase1 | Orthopoxviral Disease | Completed | 2008-08-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00431951 | Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokin… | Phase1 | Healthy | Completed | 2007-02-01 | 2008-02-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Tecovirimat Oral Capsule (Open Label) | Other | Phase PHASE3 | MPOX | TERMINATED | NCT05534984 |
| Placebo for Tecovirimat | Other | Phase PHASE3 | MPOX | TERMINATED | NCT05534984 |
| Tecovirimat Oral Capsule | Other | Phase PHASE3 | MPOX | TERMINATED | NCT05534984 |
| Placebo | Other | Phase PHASE2 | Orthopoxviral Disease | COMPLETED | NCT00907803 |
| ST-246 600 mg | Other | Phase PHASE2 | Orthopoxviral Disease | COMPLETED | NCT00907803 |
| ST-246 400 mg | Other | Phase PHASE2 | Orthopoxviral Disease | COMPLETED | NCT00907803 |
| Placebo | Other | Phase PHASE2 | Orthopoxviral Disease | COMPLETED | NCT00907803 |
| ST-246 600 mg | Other | Phase PHASE2 | Orthopoxviral Disease | COMPLETED | NCT00907803 |
| ST-246 400 mg | Other | Phase PHASE2 | Orthopoxviral Disease | COMPLETED | NCT00907803 |
| ST-246 Days 11 - 13 | Other | Phase PHASE1 | Orthopoxviral Disease | COMPLETED | NCT00728689 |
| ST-246 Days 1 - 3 | Other | Phase PHASE1 | Orthopoxviral Disease | COMPLETED | NCT00728689 |
| ST-246 Days 11 - 13 | Other | Phase PHASE1 | Orthopoxviral Disease | COMPLETED | NCT00728689 |
| ST-246 Days 1 - 3 | Other | Phase PHASE1 | Orthopoxviral Disease | COMPLETED | NCT00728689 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00431951 |
| ST-246 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00431951 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00431951 |
| ST-246 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00431951 |
| Placebo | Other | Phase PHASE3 | Smallpox | COMPLETED | NCT02474589 |
| tecovirimat | Other | Phase PHASE3 | Smallpox | COMPLETED | NCT02474589 |
| TPOXX 200Mg Capsule | Other | Preclinical | Smallpox | WITHDRAWN | NCT03972111 |
| Tpoxx | Other | Phase PHASE4 | Smallpox | COMPLETED | NCT04392739 |
| Tpoxx | Other | Phase PHASE4 | Smallpox | COMPLETED | NCT04392739 |
| Lanthanum Carbonate Chewable Tablet | Other | Phase PHASE4 | Smallpox | COMPLETED | NCT04485039 |
| calcium acetate oral tablet | Other | Phase PHASE4 | Smallpox | COMPLETED | NCT04485039 |
| sucroferric oxyhydroxide chewable tablet | Other | Phase PHASE4 | Smallpox | COMPLETED | NCT04485039 |
| sevelamer carbonate oral tablet | Other | Phase PHASE4 | Smallpox | COMPLETED | NCT04485039 |
| Tecovirimat | Other | Phase PHASE4 | Smallpox | COMPLETED | NCT04485039 |
| Lanthanum Carbonate Chewable Tablet | Other | Phase PHASE4 | Smallpox | COMPLETED | NCT04485039 |
| calcium acetate oral tablet | Other | Phase PHASE4 | Smallpox | COMPLETED | NCT04485039 |
| sucroferric oxyhydroxide chewable tablet | Other | Phase PHASE4 | Smallpox | COMPLETED | NCT04485039 |
| sevelamer carbonate oral tablet | Other | Phase PHASE4 | Smallpox | COMPLETED | NCT04485039 |
| Tecovirimat | Other | Phase PHASE4 | Smallpox | COMPLETED | NCT04485039 |
| TPOXX IV (Tecovirimat Injection, 10 mg/mL) | Other | Preclinical | Orthopox Virus Infection | NO_LONGER_AVAILABLE | NCT05380752 |
| TPOXX IV (Tecovirimat Injection, 10 mg/mL) | Other | Preclinical | Orthopox Virus Infection | NO_LONGER_AVAILABLE | NCT05380752 |
| Tecovirimat Oral Capsule (Open Label) | Other | Phase PHASE3 | MPOX | TERMINATED | NCT05534984 |
| Placebo for Tecovirimat | Other | Phase PHASE3 | MPOX | TERMINATED | NCT05534984 |
| Tecovirimat Oral Capsule | Other | Phase PHASE3 | MPOX | TERMINATED | NCT05534984 |